Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma

Five-year follow-up of S1106 demonstrates similar efficacy, MRD negativity, and 5-year survival with RH or RB, but RH was more toxic than RB. RB showed excellent efficacy and survival and less toxicity compared with a cytarabine-based regimen in transplant-eligible MCL patients.

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Kamdar, Manali, Li, Hongli, Chen, Robert W., Rimsza, Lisa M., Leblanc, Michael L., Fenske, Timothy S., Shea, Thomas C., Barr, Paul M., Phillips, Tycel J., Leonard, John P., Kahl, Brad S., Friedberg, Jonathan W., Smith, Sonali M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Stimulus Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6849956/
https://ncbi.nlm.nih.gov/pubmed/31648328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000526
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados